JP2008500963A - 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性 - Google Patents

第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性 Download PDF

Info

Publication number
JP2008500963A
JP2008500963A JP2007503063A JP2007503063A JP2008500963A JP 2008500963 A JP2008500963 A JP 2008500963A JP 2007503063 A JP2007503063 A JP 2007503063A JP 2007503063 A JP2007503063 A JP 2007503063A JP 2008500963 A JP2008500963 A JP 2008500963A
Authority
JP
Japan
Prior art keywords
hiv
antigen
immunogen
immunomodulatory oligonucleotide
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500963A5 (cg-RX-API-DMAC7.html
Inventor
クレリーチ,マリオ
バーソロミュー,リチャード
ブレイ,ドロシー
カンディマラ,エカンバー
アグラワル,サディール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Idera Pharmaceuticals Inc
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc, Hybridon Inc filed Critical Idera Pharmaceuticals Inc
Publication of JP2008500963A publication Critical patent/JP2008500963A/ja
Publication of JP2008500963A5 publication Critical patent/JP2008500963A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007503063A 2004-03-12 2005-03-11 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性 Pending JP2008500963A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55287104P 2004-03-12 2004-03-12
PCT/US2005/008238 WO2005089231A2 (en) 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Publications (2)

Publication Number Publication Date
JP2008500963A true JP2008500963A (ja) 2008-01-17
JP2008500963A5 JP2008500963A5 (cg-RX-API-DMAC7.html) 2008-05-15

Family

ID=34994209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503063A Pending JP2008500963A (ja) 2004-03-12 2005-03-11 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性

Country Status (7)

Country Link
US (1) US20050266015A1 (cg-RX-API-DMAC7.html)
EP (1) EP1729802A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008500963A (cg-RX-API-DMAC7.html)
CN (1) CN101217973A (cg-RX-API-DMAC7.html)
AU (1) AU2005222909B2 (cg-RX-API-DMAC7.html)
CA (1) CA2557443A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005089231A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
JP4726630B2 (ja) * 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
OA13246A (en) * 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6010068912, "Immune Response Licenses Hybridon’s AMPLIVAX vaccine adjuvant", BIOTECH Patent News, 200310, Vol.17, No.10, p.14−15 *
JPN6010068913, KANDIMALLA, E.R., et al., "Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomod", Nucleic Acids Research, 2003, Vol.31, No.9, p.2393−2400 *
JPN6010068914, HORNER, A.A., et al., "Immunostimulatory DNA−Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic an", The Journal of Immunology, 2001, Vol.167, p.1584−1591 *
JPN6010068915, LIMSUWAN, A., et al., "Safety and immunogenicity of REMUNE TM in HIV−infected Thai subjects", Vaccine, 1998, Vol.16, No.2/3, p.142−149 *

Also Published As

Publication number Publication date
CA2557443A1 (en) 2005-09-29
AU2005222909B2 (en) 2010-03-11
AU2005222909A1 (en) 2005-09-29
EP1729802A2 (en) 2006-12-13
EP1729802A4 (en) 2009-12-16
US20050266015A1 (en) 2005-12-01
WO2005089231A3 (en) 2007-12-06
WO2005089231A2 (en) 2005-09-29
CN101217973A (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
CA2372960C (en) Hiv immunogenic compositions and methods
US6737066B1 (en) HIV immunogenic compositions and methods
Sjölander et al. Immune responses to ISCOM® formulations in animal and primate models
Courtney et al. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens
EP1198249B1 (en) Use of cpg as an adjuvant for hiv vaccine
Borsutzky et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant
KR100622716B1 (ko) 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신
JP2012006949A (ja) アジュバント混合製剤
Becker et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant
Huang et al. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses
AU2005222909B2 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
US20030044428A1 (en) Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US20070253979A1 (en) Immunogenic Hiv Compositions and Related Methods
CN101360514A (zh) 基于双酰氧基丙基半胱氨酸缀合物及其衍生物的新佐剂及其在药物组合物中的用途
WO2015036061A1 (en) Novel compositions
O'Hagan et al. Novel adjuvants and delivery systems for HIV vaccines
HK1114789A (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
TW202436326A (zh) 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
KR20070019635A (ko) 면역원성 hiv 조성물 및 이와 관련된 방법
MX2008006488A (es) Nuevos adyuvantes con base en conjugados de bisaciloxipropilcisteina y derivados y sus usos en composiciones farmaceuticas
Poonam Induction of strong cellular immune responses in the gut mucosa against HIV-1 using a combination vaccine of recombinant Clostridium perfringens and HIV-1 virus like particles
ZA200108559B (en) HIV immunogenic compositions and methods.
MXPA01010784A (en) Hiv immunogenic compositions and methods
SA02230071B1 (ar) تركيبات مولدة للمضاد ومساعدة تشمل فوسفات جلوكوز أمين أمينوالكيل و -il-12 أو csf gm-

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110712